Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

Similar articles for PubMed (Select 22092408)

1.

In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.

Anz D, Eiber S, Scholz C, Endres S, Kirchner T, Bourquin C, Mayr D.

Histopathology. 2011 Nov;59(5):965-74. doi: 10.1111/j.1365-2559.2011.04040.x.

PMID:
22092408
2.

Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer.

Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K, Aoki D.

Int J Gynecol Cancer. 2011 Dec;21(9):1628-34. doi: 10.1097/IGC.0b013e31822c271f.

PMID:
21897268
3.

Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F.

Clin Cancer Res. 2008 Apr 15;14(8):2413-20. doi: 10.1158/1078-0432.CCR-07-4491.

4.

Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.

Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C, Sun Y.

J Cancer Res Clin Oncol. 2010 Oct;136(10):1585-95. doi: 10.1007/s00432-010-0816-9. Epub 2010 Mar 11.

PMID:
20221835
5.

Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer.

Xu L, Xu W, Qiu S, Xiong S.

Clin Immunol. 2010 Jun;135(3):466-75. doi: 10.1016/j.clim.2010.01.014. Epub 2010 Feb 24.

PMID:
20181533
6.

Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.

Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, Seow HF.

Immunol Lett. 2006 Feb 15;102(2):229-36. Epub 2005 Oct 7.

PMID:
16246429
7.

Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast.

Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, Pringle GA, Zhang X, Fu L.

Mod Pathol. 2008 Sep;21(9):1101-7. doi: 10.1038/modpathol.2008.72. Epub 2008 May 9.

8.

Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B.

J Clin Oncol. 2009 Jan 10;27(2):186-92. doi: 10.1200/JCO.2008.18.7229. Epub 2008 Dec 8.

9.

CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.

Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L.

Breast Cancer Res Treat. 2011 Nov;130(2):645-55. doi: 10.1007/s10549-011-1647-3. Epub 2011 Jun 30.

PMID:
21717105
10.

Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M.

Cancer Immunol Immunother. 2010 May;59(5):653-61. doi: 10.1007/s00262-009-0781-9. Epub 2009 Nov 12.

PMID:
19908042
11.

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW.

Cancer Immunol Immunother. 2009 Mar;58(3):449-59. doi: 10.1007/s00262-008-0583-5. Epub 2008 Sep 13.

PMID:
18791714
12.

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.

Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J.

Gut. 2009 Apr;58(4):520-9. doi: 10.1136/gut.2008.158824. Epub 2008 Nov 20.

PMID:
19022917
13.

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.

Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21.

14.

An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.

Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 May;127(1):99-108. doi: 10.1007/s10549-010-0987-8. Epub 2010 Jun 17.

PMID:
20556505
16.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.

Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F.

J Pathol. 2011 Jul;224(3):389-400. doi: 10.1002/path.2866. Epub 2011 Mar 25.

PMID:
21437909
17.

PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.

Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, Wang J, Yuan F, Sun L, Yu Q, Jin X, Wang J, Shen K.

Cancer Immunol Immunother. 2014 Apr;63(4):395-406. doi: 10.1007/s00262-014-1519-x. Epub 2014 Feb 11.

PMID:
24514954
18.
19.

The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.

Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH.

Gynecol Oncol. 2008 Aug;110(2):216-21. doi: 10.1016/j.ygyno.2008.04.021. Epub 2008 Jun 3.

PMID:
18533240
20.

Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.

Droeser R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, Oertli D, Tapia C.

BMC Cancer. 2012 Apr 3;12:134. doi: 10.1186/1471-2407-12-134.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk